OPPORTUNITY
PrEEmiuM students will be perfectly trained to meet the needs of biopharma small and medium
enterprises in Canada and multinationals alike, may it be in R&D, scale-up or quality
control. First and foremost, they will ensure an efficient dialogue with their peers from other
fields of expertise.
As PrEEmiuM trainees will have experienced the entire continuum of drug development from R&D
to manufacturing, they will be uniquely prepared to access key positions in an industrial sector
that needs an optimal integration of the concepts of ‘Developability’
(research pharmacist), ‘Scalability’ (engineering) and
‘Commerciability’ (regulatory agencies/industry) from the onset of drug
discovery.
Mission
The objective of PrEEmiuM is to don young engineers and
scientists with a global vision of (bio)pharmaceutical engineering, focused on the
continuum from nano-medicine formulation to scale-up. At full capacity,
the PrEEmiuM cohort will comprise 20 PhDs, 10 MScs and 3 BScs per
year.
Research themes
PrEEmiuM articulates around three research training
thrusts covering the entire ecosystem of innovative drug delivery platforms and
their specific challenges:
Process Engineering of
Virus-like particles
as an alternative to the classical egg-based vaccine
manufacturing process
Non-viral vectors
for nucleic acid delivery and nano-medicines based
on protein conjugation or encapsulation
Emerging pharmaceutical forms
to exploit the full potential of class IV drugs
according to the Biopharmaceutics Classification System